Basal ganglia dopamine loss due to defect in purine recycling

Neurobiology of Disease

Volumn 26, Issue 2, 2007, Pages 396-407

  Egami, Kiyoshi ^a   Yitta, Silaja ^a   Kasim, Suhail ^a   Lewers, J Chris ^a   Roberts, Rosalinda C ^b   Lehar, Mohamed ^c   Jinnah, H A ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; PURINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CELL FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; FEMALE; KNOCKOUT MOUSE; LESCH NYHAN SYNDROME; MALE; MESENCEPHALON; MORPHOMETRICS; MOUSE; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PURINE METABOLISM; STEREOMETRY;

ANIMALS; BASAL GANGLIA; CELL LINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GLIOSIS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, TRANSMISSION; NERVE DEGENERATION; NEURAL PATHWAYS; PRESYNAPTIC TERMINALS; PURINES; SUBSTANTIA NIGRA; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 34147100640     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.01.010     Document Type: Article

References (51)

1. About-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7 (2006) 207-219
2. Antonarakis S.E., and Beckmann J.S. Mendelian disorders deserve more attention. Nat. Rev. Genet. 4 (2006) 277-282
3. Arluison M., Dietl M., and Thibault J. Ultrastructural morphology of dopaminergic nerve terminals and synapses in the striatum of the rat using tyrosine hydroxylase immunocytochemistry: a topographical study. Brain Res. Bull. 13 (1984) 269-285
4. Bayer V.E., and Pickel V.M. GABA-labeled terminals form proportionally more synapses with dopaminergic neurons containing low densities of tyrosine hydroxylase-immunoreactivity in rat ventral tegmental area. Brain Res. 559 (1991) 44-55
5. Berod A., Hartman B.K., and Pujol J.F. Importance of fixation in immunohistochemistry: use of formaldehyde solutions at variable pH for the localization of tyrosine hydroxylase. J. Histochem. Cytochem. 29 (1981) 844-850
6. Chadi G., Moller A., Rosen L., Janson A.M., Agnati L.A., Goldstein M., Ogren S.O., Pettersson R.F., and Fuxe K. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp. Brain Res. 97 (1993) 145-158
7. Choi H.K., Won L.A., Kontur P.J., Hammond D.N., fox A.P., Wainer B.H., Hoffmann P.C., and Heller A.C. Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res. 552 (1991) 67-76
8. Chu Y., Le W., Kompoliti K., Jankovic J., Mufson E.J., and Kordower J.H. Nurr1 in Parkinson's disease and related disorders. J. Comp. Neurol. 494 (2006) 495-514
9. Chun H.S., Yoo M.S., DeGiorgio L.A., Volpe B.T., Peng D., Baker H., Peng C., and Son J.H. Marked dopaminergic cell loss subsequent to developmental, intranigral expression of glial cell line-derived neurotrophic factor. Exp. Neurol. 173 (2002) 235-244
10. Church W.H., and Ward V.L. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res. Bull. 33 (1994) 419-424
11. Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., and Ross R.A. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res. 49 (1989) 219-225
12. Clementi E., Racchetti G., Zacchetti D., Panzeri M.C., and Meldolesi J. Differential expression of markers and activities in a group of PC12 nerve cell clones. Eur. J. Neurosci. 4 (1992) 944-953
13. Cookson M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74 (2005) 29-52
14. Darchen F., Masuo Y., Vial M., Rostene W., and Scherman D. Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserin. Neuroscience 33 (1989) 341-349
15. Davis J.W., Grandinetti A., Waslien C.I., Ross G.W., White L.R., and Morens D.M. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am. J. Epidemiol. 144 (1996) 480-484
16. de Lau L.M., Koudstaal P.J., Hofman A., and Breteler M.M. Serum uric acid and the risk of Parkinson disease. Ann. Neurol. 58 (2005) 797-800
17. De Olmos J.S., and Ingram W.R. An improved cupric-silver method for impregnation of axonal and terminal degeneration. Brain Res. 33 (1971) 523-529
18. Dube L., Smith A.D., and Bolam J.P. Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum. J. Comp. Neurol. 267 (1988) 455-471
19. Ernst M., Zametkin A.J., Matochik J.A., Pascualvaca D., Jons P.H., Hardy K., Hankerson J.G., Doudet D.J., and Cohen R.M. Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N. Engl. J. Med. 334 (1996) 1568-1572
20. Ferre S., Fuxe K., Von Euler G., Johansson B., and Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience 51 (1992) 501-512
21. Furukawa Y. Update on dopa-responsive dystonia: locus heterogeneity and biochemical features. Adv. Neurol. 94 (2004) 127-138
22. Groves P.M., Linder J.C., and Young S.J. 5-Hydroxydopamine-labeled dopaminergic axons: three-dimensional reconstructions of axons, synapses and postsynaptic targets in rat neostriatum. Neuroscience 58 (1994) 593-604
23. Haycock J.W., Becker L., Ang L., Furukawa Y., Hornykiewicz O., and Kish S. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J. Neurochem. 87 (2003) 574-585
24. Heller A., Price S., and Won L. Glial-derived neurotrophic factor (GDNF) induced morphological differentiation of an immortalized monoclonal hybrid dopaminergic cell line of mesencephalic origin. Brain Res. 725 (1996) 132-136
25. Hirsch E., Graybiel A.M., and Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
26. Hyland K., Kasim S., Egami K., Arnold L.A., and Jinnah H.A. Tetrahydrobiopterin and brain dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J. Inherit. Metab. Dis. 27 (2004) 165-178
27. Jackson-Lewis V., Vila M., Djaldetti R., Guegan C., Liberatore G., Liu J., O'Malley K.L., Burke R.E., and Przedborski S. Developmental cell death in dopaminergic neurons of the substantia nigra of mice. J. Comp. Neurol. 424 (2000) 476-488
28. Jinnah H.A., Hess E.J., Wilson M.C., Gage F.H., and Friedmann T. Localization of hypoxanthine-guanine phosphoribosyltransferase mRNA in the mouse brain by in situ hybridization. Mol. Cell. Neurosci. 3 (1992) 64-78
29. Jinnah H.A., Langlais P.J., and Friedmann T. Functional analysis of brain dopamine systems in a genetic mouse model of Lesch-Nyhan syndrome. J. Pharmacol. Exp. Ther. 263 (1992) 596-607
30. Jinnah H.A., Page T., and Friedmann T. Brain purines in a genetic mouse model of Lesch-Nyhan disease. J. Neurochem. 60 (1993) 2036-2045
31. Jinnah H.A., Wojcik B.E., Hunt M.A., Narang N., Lee K.Y., Goldstein M., Wamsley J.K., Langlais P.J., and Friedmann T. Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J. Neurosci. 14 (1994) 1164-1175
32. Jinnah H.A., Jones M.D., Wojcik B.E., Rothstein J.D., Hess E.J., Friedmann T., and Breese G.R. Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J. Neurochem. 72 (1999) 225-229
33. Jinnah H.A., DeGregorio L., Harris J.C., Nyhan W.L., and O'Neill J.P. The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat. Res. 463 (2000) 309-326
34. Jinnah H.A., Visser J.E., Harris J.C., Verdu A., Larovere L., Ceballos-Picot I., Neychev V., Torres R.J., Dulac O., Desguerre I., Schretlen D.J., Robey K.L., Barabas G., Bloem B.R., Nyhan W.L., Kremer R., Puig G.E., and Reich J.G. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 129 (2006) 1201-1217
35. King J.C., Lechan R.M., Kugel G., and Anthony E.L.P. Acrolein: a fixative for immunocytochemical localization of peptides in the central nervous system. J. Histochem. Cytochem. 31 (1983) 62-68
36. Koike T., and Takashima A. Clonal variability of PC12 pheochromocytoma cells with respect to catecholamine biosynthesis. J. Neurochem. 42 (1984) 1472-1475
37. Lin J.C., and Rosenthal A. Molecular mechanisms controlling the development of dopaminergic neurons. Semin. Cell Dev. Biol. 14 (2003) 175-180
38. Lloyd K.G., Hornykiewicz O., Davidson L., Shannak K., Farley I., Goldstein M., Shibuya M., Kelley W.N., and Fox I.H. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N. Engl. J. Med. 305 (1981) 1106-1111
39. Mikolaenko I., Rao L.M., Roberts R.C., Kolb B., and Jinnah H.A. A Golgi study of neuronal architecture in a genetic mouse model for Lesch-Nyhan disease. Neurobiol. Dis. 20 (2005) 479-490
40. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
41. Nelson J.A., Carpenter J.W., Rose L.M., and Adamson D.J. Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res. 35 (1975) 2872-2878
42. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., and Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 16 (1996) 436-447
43. Pickel V.M., Beckley S.C., Joh T.H., and Reis D.J. Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res. 225 (1981) 373-385
44. Saito Y., and Takashima S. Neurotransmitter changes in the pathophysiology of Lesch-Nyhan syndrome. Brain Dev. 22 Suppl. 1 (2000) S122-S131
45. Saito Y., Ito M., Hanaoka S., Ohama E., Akaboshi S., and Takashima S. Dopamine receptor upregulation in Lesch-Nyhan syndrome: a postmortem study. Neuropediatrics 30 (1999) 66-71
46. Smidt M.P., Smits S.M., and Burbach J.P.H. Molecular mechanisms underlying midbrain dopamine neuron development and function. Eur. J. Pharmacol. 480 (2003) 75-88
47. Visser J.E., Baer P.R., and Jinnah H.A. Lesch-Nyhan syndrome and the basal ganglia. Brain Res. Rev. 32 (2000) 449-475
48. Wilson J.M., and Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 16 (1996) 3507-3510
49. Wong D.F., Harris J.C., Naidu S., Yokoi F., Marenco S., Dannals R.F., Ravert H.T., Yaster M., Evans A., Rousset O., Bryan R.N., Gjedde A., Kuhar M.J., and Breese G.R. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5539-5543
50. Zaborszky L., and Vadasz C. The midbrain dopaminergic system: anatomy and genetic variation in dopamine neuron number of inbred mouse strains. Behav. Genet. 31 (2001) 47-59
51. Zeevalk G.D., Bernard L.P., Song C., Gluck J.P., and Ehrhart J. Mitochondrial inhibition and oxidative stress: reciprocating players in neurodegeneration. Antioxid. Redox Signal. 7 (2005) 1117-1139